The use of fetal DNA in maternal plasma for noninvasive prenatal diagnosis of trisomy 21 (T21) is an actively researched area. We propose a novel method of T21 detection that combines fetal-specific epigenetic and genetic markers.
a generally usable technique for noninvasive prenatal diagnosis.
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Screening for trisomy 21 (T21) 5 constitutes an important component of modern obstetrics care in many countries. Common screening methods routinely available in prenatal clinics target the epiphenomena associated with the chromosomal aneuploidy rather than directly targeting the actual chromosome dosage in the fetus (1, 2 ) . For a definitive test, conventional screening programs require invasive procedures such as chorionic villus sampling and amniocentesis; however, such methods can lead to procedure-related fetal loss (3) (4) (5) .
The discovery of cell-free fetal DNA in maternal plasma in 1997 has offered new possibilities for noninvasive prenatal diagnosis (6, 7 ) . Detection of the fetal-derived, paternally inherited genetic materials in maternal plasma samples has allowed the prenatal determination of fetal Rhesus D blood group (8, 9 ) and determination of fetal sex for sex-linked disorders (10 ) . The development of noninvasive prenatal diagnostic tests for fetal chromosomal aneuploidies, however, has been more challenging.
Two main groups of approaches have been developed for the direct detection of T21 from the analysis of nucleic acids in maternal plasma. The first group involves the analysis of allelic ratios of single nucleotide polymorphisms (SNPs) present in a fetal-specific nucleic acid marker (7 ) . Examples of this approach include the analysis of circulating placental mRNA (the RNA-SNP approach) (11 ) and DNA-methylation markers (the epigenetic allelic-ratio approach) (12 ) . The main disadvantage of the allelic ratio-based approach is that these methods are applicable only to fe-tuses that are heterozygous for the analyzed SNP. The second group of approaches uses single moleculecounting methods (13 ) such as digital PCR (14 ) and massively parallel genomic sequencing (15, 16 ) . In these approaches, individual plasma DNA molecules are counted. The precision of such methods allows the detection of the slight increase in chromosome 21-derived DNA molecules in the plasma of a pregnant woman carrying a T21 fetus. One disadvantage of the latter approaches is that counting of an extremely large number of molecules is required for markers with no fetal specificity (e.g., random sequences from chromosome 21), as is exemplified in recent experiments that used massively parallel genomic sequencing to analyze millions of molecules per case (15, 16 ) . This requirement is achievable with the use of expensive equipment and reagents and the use of relatively complex bioinformatics methods.
We propose a new approach for the noninvasive prenatal detection of T21 from maternal plasma that is based on measuring the ratio of the concentrations of a fetal-specific DNA-methylation marker on chromosome 21 and a fetal-specific DNA marker on a reference chromosome. We call this the epigenetic-genetic (EGG) chromosome-dosage approach. In contrast with the epigenetic allelic-ratio approach described above, the EGG approach does not require the fetalspecific DNA-methylation marker and the SNP to be present together within a short stretch of DNA; thus, population coverage is much easier to achieve. We also demonstrate that with a target locus on chromosome 21 and another on a reference chromosome, the EGG approach is more precise than an approach based purely on epigenetic markers.
For the EGG approach to work, however, it is crucial to have a good fetal-specific DNA-methylation marker on chromosome 21. The ideal marker would be hypermethylated in the fetus and hypomethylated in maternal blood cells so that a methylation-sensitive restriction endonuclease (MSRE) could be used to digest away the maternal sequences. Indeed, previous work has shown that the promoter of the RASSF1A 6 gene [Ras association (RalGDS/AF-6) domain family member 1A; GenBank accession no. NM_007182] is one such marker, except that it is on chromosome 3 (17, 18 ) . Despite reports of a number of fetal DNAmethylation markers on chromosome 21 (19 -21 ) , a chromosome 21 marker that has characteristics comparable to RASSF1A has yet to be found. We thus began our study by looking for such a marker with combined bisulfite restriction analysis (COBRA) (22 ) 
SCREENING OF DIFFERENTIALLY METHYLATED REGIONS ON

CHROMOSOME 21
COBRA (22 ) was used to assess the methylation status of genomic sequences on chromosome 21 in DNA samples from placentas and maternal blood cells. The COBRA procedure is described in the online Data Supplement.
The PCR products of the HLCS locus produced in the COBRA analysis were used for cloning and bisulfite sequencing. The detailed protocol is presented in the online Data Supplement. The frequency of methylated sites was calculated by dividing the total number of methylated CpG sites by the total number of CpG sites in the cloned region (18 ) .
CONVENTIONAL REAL-TIME QUANTITATIVE PCR ANALYSIS OF THE HLCS LOCUS
We used the COBRA-screening and bisulfite sequencing results to develop an MSRE-digestion assay. We then used real-time quantitative PCR analysis to target HLCS locus region B2, which is hypermethylated in the placenta and unmethylated in maternal blood cells. The procedures are detailed in the online Data Supplement. The sequences for the primers and probe are listed in Table 1 . Results for genomic DNA samples were expressed as a methylation index, which was calculated by dividing the HLCS copy number obtained after enzyme digestion by that obtained with mock digestion. We analyzed maternal plasma DNA to show the postpartum clearance of the hypermethylated HLCS molecules.
CHROMOSOME-DOSAGE ANALYSIS BY MICROFLUIDICS DIGITAL PCR
We used PCR analysis on a microfluidics digital PCR platform to compare chromosome dosages for chromosome 21 and the reference markers (23, 24 ) . The loci for an epigenetic-epigenetic comparison were HLCS on chromosome 21 and RASSF1A on chromosome 3 (18 ) . Both are hypermethylated fetal DNA markers. The loci for an EGG comparison were HLCS on chromosome 21 and ZFY (zinc finger protein, Y-linked) on chromosome Y from pregnancies with a male fetus.
MSRE digestion.
Restriction enzyme BstUI (New England Biolabs) was used to digest hypomethylated DNA. Extracted DNA was digested with BstUI at 60°C for 16 h. For placental tissues and maternal blood cells, we used 40 U BstUI to digest 200 ng DNA. A mockdigested aliquot without added enzyme was included. For plasma samples, we used 20 -60 U BstUI to digest the DNA from 3.4 -9.1 mL of plasma.
Microfluidics digital PCR analysis. Microfluidics digital PCR assays were designed for the HLCS, RASSF1A, and ZFY loci (see Fig. S1 in the online Data Supplement), which represent the dosages of chromosome 21, chromosome 3, and chromosome Y, respectively. The ZFX (zinc finger protein, X-linked) and ZFY assays and the basis of the digital PCR analysis have been described previously (25 ) . The sequences of primers and probes are listed in Table 1 . The digital PCR experiments were carried out on the BioMark System (Fluidigm) with the 12.765 Digital Arrays (Fluidigm). Each array consisted of 12 panels, each of which was further partitioned into 765 reaction wells. With each panel, the reaction was set up as a 10-L mixture at the following final concentrations: 1ϫ TaqMan Universal PCR Master Mix (Applied Biosystems), 125 nmol/L hydrolysis probe (Applied Biosystems) (Table 1) , and 900 nmol/L of the forward and reverse primers (Integrated DNA Technologies) ( Table 1 ). The reaction mixture was diluted with the assay loading buffer and sample loading buffer according to the manufacturer's protocol. The input DNA volume was 3.5 L. Table 1 shows the specific thermal cycling conditions for each assay. The HLCS and RASSF1A assays were performed as monoplex assays. The ZFX/ZFY assays were performed as a duplex reaction.
The fetal specificity of the assays was determined by detecting the number of copies of HLCS, RASSF1A, ZFX, and ZFY in BstUI-digested samples of genomic DNA and plasma DNA.
Chromosome-dosage results obtained with the epigeneticepigenetic and EGG approaches. Digital PCR analyses of the HLCS, RASSF1A, ZFX, and ZFY loci were performed on euploid and T21 samples of placental DNA after BstUI restriction enzyme digestion. For the analysis of maternal plasma, we compared the ratios of HLCS to ZFY in BstUI-digested DNA samples obtained from euploid and T21 pregnancies. Samples that used 1 digestion-reaction tube were diluted and distributed into 6 panels. Samples that used 2 digestion-reaction tubes (with a larger volume) were diluted and distributed into 12 panels, and so on.
STATISTICAL ANALYSIS
SigmaStat 3.5 software (Systat Software) was used for statistical analyses.
Results
COBRA SCREENING OF DIFFERENTIALLY METHYLATED REGIONS ON CHROMOSOME 21
Of the 35 promoter regions on chromosome 21 selected for COBRA screening of differential methylation, 30 were not associated with CpG islands (CGIs); the other 5 were associated with CGIs. The criteria for defining a CGI were as described previously (26 ) . We obtained DNA sequences proximal to transcription start sites (Ϫ1 kb to ϩ500 bp, the transcription start site being 0) for the 35 promoters from the March 2006 human reference sequence of the UCSC Genome Bioinformatics Database (http://www.genome.ucsc.edu/; NCBI Build 36.1) and designed 51 COBRA assays to compare the methylation patterns of placental tissues and maternal blood cells (see Table S1 in the online Data Supplement).
With the 51 assays, we compared the methylation profiles of the promoter regions for placental tissues collected from the first and third trimesters with those for maternal blood cells (see Table S1 in the online Data Supplement). Of the screened regions, the putative promoter regions of HLCS and C21orf81 (chromosome 21 open reading frame 81; GenBank accession no. AF326257) were identified by COBRA to be differentially methylated in placental tissues and maternal blood cells. Representative COBRA results are illustrated in Fig. S2A in the online Data Supplement for HLCS region B2, which was hypermethylated in placental tissues compared with maternal blood cells, and in Fig. S2B in the online Data Supplement for C21orf81, which was hypermethylated in maternal blood cells compared with placental tissues.
CLONING AND BISULFITE SEQUENCING ANALYSIS OF THE HLCS LOCUS
We used cloning and bisulfite sequencing experiments to further analyze the methylation of the HLCS region at the resolution of a single molecule; the results are shown in Fig. 1 . The HLCS sequencing results confirmed that HLCS is hypermethylated in placental cells at a methylated site frequency of 0.435-0.699. Although we detected a low methylation level in maternal blood cell samples at the 3Ј end (i.e., position Ϫ57 to ϩ111) of the target sequence (methylated site frequency Ͻ0.100), we observed almost no methylation of CpG sites from Ϫ232 to Ϫ67. We did not further investigate the potential hypomethylated fetal DNA marker, C21orf81, because our aim in the current study was to develop hypermethylated fetal DNA markers.
REAL-TIME QUANTITATIVE PCR FOR MSRE-DIGESTED PLACENTAL, MATERNAL BLOOD CELL, AND PLASMA
DNA SAMPLES
We compared the methylation profiles of the putative promoter region of HLCS from 8 maternal blood cell samples with the profiles from 2 firsttrimester and 2 third-trimester placental tissue samples collected from euploid pregnancies. The results of restriction enzyme digestion followed by realtime quantitative PCR analysis are shown in Previous data suggested that the placenta was the predominant source of fetal DNA (27 ) and that maternal blood cells were the main contributor of the background maternal DNA (28 ) detectable in maternal plasma. We therefore hypothesized that the placenta-specific fraction of the HLCS DNA molecules-namely the methylated or nondigestible fraction-could be detected in maternal plasma. We collected 10 pairs of pre-and postdelivery samples of third-trimester maternal plasma for analysis. Positive HLCS signals were obtained for all of the enzyme-digested predelivery plasma samples. The clearance pattern for the enzyme-treated pre-and postdelivery plasma samples suggested that the digestion-resistant HLCS molecules were pregnancy specific (P ϭ 0.002, Wilcoxon signed rank test; see Fig. S4A in the online Data Supplement). Median HLCS concentrations were 730 copies/mL (IQR, 650 -790 copies/mL) and 35 copies/mL (IQR, 26 -46 copies/mL) for enzyme-treated pre-and postdelivery plasma samples, respectively. With mock digestion, we expected unmethylated maternal HLCS molecules to be detected in addition to digestionresistant placental HLCS molecules, and no postpartum clearance was observed (P ϭ 0.16, Wilcoxon signed rank test; see Fig. S4B in the online Data Supplement). Median HLCS concentrations were 2300 copies/mL (IQR, 1900 -2700 copies/mL) and 2100 copies/mL (IQR, 1700 -2400 copies/mL) for mockdigested pre-and postdelivery plasma samples, respectively.
MICROFLUIDICS DIGITAL PCR ANALYSIS OF MSRE-DIGESTED DNA
We compared chromosome dosages for the chromosome 21 and reference chromosome markers on a microfluidics digital PCR platform. The chromosome 21 marker was hypermethylated HLCS, and the reference markers on chromosome 3 and chromosome Y were hypermethylated RASSF1A and male-specific ZFY, respectively.
Two pairs of placental tissue and maternal blood cell samples were used to check the performance of the HLCS and RASSF1A assays with and without enzyme digestion. The ZFX/ZFY duplex assay also was performed [GenBank accession nos. NM_003410 (ZFX) and NM_003411 (ZFY)]. Because there is no BstUI site within the amplified regions of ZFX and ZFY, we expected the copy number not to be affected by the enzyme digestion. Two postdelivery maternal plasma samples were used to test the postpartum clearance of the digestion-resistant HLCS and RASSF1A molecules.
One microfluidics digital PCR panel with 765 reaction wells was used for each assay of each of the genomic DNA samples. For the postdelivery maternal plasma samples, enzyme-digested DNA was distributed into 2 panels for the scoring of any wells with positive signals. Results for the genomic DNA and plasma DNA samples are summarized in Tables S2A  and S2B , respectively, in the online Data Supplement. We counted the number of wells positive for each target locus. The actual number of molecules distributed into the panel followed the Poisson distribution and was corrected with the following equation: Target ϭ Ϫln(E/N) ϫ N, where Target is the Poisson-corrected counts of the target molecules, E is the number of negative (empty) wells, and N is the total number of digital PCRs in the experiment.
Results from the BstUI-digested samples of placental DNA showed that about 60%-70% of the HLCS and RASSF1A molecules remained detectable, compared with the mock-digested samples. In the samples of maternal blood DNA, the hypomethylated RASSF1A molecules were completely digested by the BstUI treatment, whereas a few HLCS molecules remained detectable in the samples. For the ZFY and ZFX assays, there was no change in the copy numbers in the mock-or BstUI-digested DNA samples (see Table S2A in the online Data Supplement).
Analysis of postdelivery maternal plasma revealed extremely low levels of both the HLCS and RASSF1A molecules after BstUI digestion (Table S2B in the online Data Supplement).
CHROMOSOME-DOSAGE ANALYSIS OF PLACENTAL DNA SAMPLES
The HLCS and RASSF1A assays were applied to 10 euploid and 12 T21 placental DNA samples from pregnancies with male fetuses. Four digital PCR panels were counted for each assay (Fig. 2A) . The ratios of the numbers of positive HLCS and RASSF1A amplifications in the euploid and T21 samples were significantly different (P ϭ 0.005, Mann-Whitney rank sum test); however, the 2 groups showed a large degree of overlap (Fig. 3A) . We calculated a reference interval, defined as the mean ratio of HLCS to RASSF1A Ϯ 1.96 SD, for the euploid samples as 0.86 -1.63. More than half of the T21 cases fell within the reference interval. The heterogeneity in the methylation density of the 2 loci across different samples may have contributed to the large interindividual variation in the HLCS/RASSF1A ratio. Solving this precision problem would require a more stable baseline for comparing the dosages of the euploid and T21 DNA samples.
We then turned to a fetal-specific genetic marker, the ZFY locus, to serve as a baseline for comparing chromosome dosages in pregnancies involving a male fetus. We called this strategy the EGG approach.
The same restriction enzyme-digested placental DNA samples used for the HLCS and RASSF1A comparison were subjected to the ZFY digital PCR analysis ( Fig. 2A) . The total copy number from 4 panels was used as the reference baseline for the total copy number of the HLCS molecules obtained above. A reference interval, defined as the mean ratio of HLCS to ZFY Ϯ 1.96 SD, was calculated from the euploid samples as 1.08 -1.62. All of the T21 samples had a ratio greater than the upper reference limit (P Ͻ 0.001, MannWhitney rank sum test; Fig. 3B ).
EGG ANALYSIS OF MATERNAL PLASMA DNA
We obtained 8 maternal plasma samples from each of the 3 trimesters among pregnancies involving euploid fetuses, for a total of 24 samples. After BstUI digestion, each DNA sample was analyzed with the HLCS and ZFY assays in at least 6 panels on the microfluidics chips (Fig. 2B) . The total number of Poisson-corrected positive wells was used to calculate the ratio of HLCS to ZFY in each sample.
A reference interval of 1.49 -2.88 was calculated for the 24 maternal plasma samples from euploid pregnancies. The ratio of 1 euploid DNA sample fell outside the reference interval. The fact that this sample dried up during SpeedVac concentration and had to be reconstituted with water during sample preparation might explain this apparent outlier. In contrast, all 5 maternal plasma samples from T21 pregnancies had a ratio of HLCS to ZFY that was greater than the upper reference limit (P Ͻ 0.001, Mann-Whitney rank sum test; Fig. 4 ). The data showed that the EGG approach can detect fetal T21 noninvasively in maternal plasma samples.
Discussion
In this study, we used COBRA mainly to screen for promoter regions on chromosome 21 that are not associated with CGIs. This approach differs from that of a previous study, which mainly targeted CGIs on chromosome 21 in a search for loci that were differentially methylated in placental tissues and blood cells (19 ) . In the first part of this study, we successfully identified a new hypermethylated fetal DNA marker on chromosome 21, the promoter region of the HLCS gene. The hypermethylated nature of this marker allows it to be detected relatively easily in maternal plasma with MSRE digestion and PCR amplification.
We then used HLCS to demonstrate that the novel EGG approach is a feasible method for analyzing fetal chromosome dosage. The main advantage of the EGG method over the previously described epigenetic allelic-ratio analysis (12 ) is that we have bypassed the requirement of the latter method for both the epigenetic target and the genetic target (i.e., the SNP) to be present in the same locus and within a short distance of each other. In this proof-of-concept study, we used the ZFY gene on the Y chromosome as a model for the fetal-specific genetic target. Additional Ychromosomal markers can also be included. Indeed, any fetal-specific genetic target (e.g., a SNP allele or a gene that the fetus has inherited from the father but is absent in the pregnant mother) can be used. We envision the relatively easy development of a panel of such markers that would ensure broad population coverage of this approach and allow pregnancies with female fetuses to be analyzed.
We also demonstrated that the EGG approach has greater power to distinguish T21 than an approach based purely on epigenetic markers, e.g., the ratio of hypermethylated HLCS to hypermethylated RASSF1A. We believe that one possible explanation for the suboptimal performance of the latter approach is the vari- The HLCS and RASSF1A assays were run as monoplex reactions, and the ZFX/ZFY assays were run as duplex reactions. Each chip is divided into 12 panels, each of which is further compartmentalized into 765 reaction wells. Reaction wells with positive amplifications are shown as colored dots, and reaction wells with no amplification are shown as gray dots. (A), Illustration of digital PCR results for enzyme-digested euploid placental DNA samples. Four panels were counted for each sample; hence, each chip could accommodate 3 samples. HLCS, RASSF1A, and ZFY are shown in red; ZFX is shown in blue. (B), Illustration of digital PCR results for a sample of enzyme-digested DNA from maternal plasma. DNA from the sample was evenly distributed in all 12 panels. Note that for maternal plasma analysis, the copy number of ZFY (fetal DNA) is much less than that of ZFX (fetal plus maternal DNA). HLCS and ZFY are shown in red; ZFX is shown in blue.
ability in the level of DNA methylation of individual fetal-derived HLCS and RASSF1A molecules, as can be seen in Fig. 1 and in previously published bisulfite sequencing results (18 ) . Thus, one would expect that a ratio determined from these 2 potentially varying parameters would have a wider reference interval than a ratio in which one of the parameters is a relatively stable genetic marker (as in the EGG approach).
In this study, we have used microfluidics digital PCR as the detection and measurement platform because previous results have shown it to be a highly precise analytical method (25, 29 ) . We envision that the EGG approach can also be implemented in variations of this molecular-counting theme, e.g., by targeted sequencing with a "next-generation" sequencer. In fact, because both HLCS and ZFY are fetal-specific markers in maternal plasma, it should be possible to detect fetal aneuploidy in maternal plasma by EGG analysis with nondigital platforms, such as conventional real-time quantitative PCR.
The development of fetal epigenetic markers on the other chromosomes important for prenatal screening (e.g., chromosomes 18 and 13) would further broaden the usefulness of the EGG approach.
